1st Quarter - Report

FORBES-TATE for GENENTECH

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 American Research and Competitiveness Act of 2011; Issues related to 340B

LobbyistCovered position, as disclosed
JERRY DRISCOLL —
JEFFREY FORBES —
ELIZABETH GREER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 942 (113th)

Trade (domestic/foreign) TRD

Trade related issues.

LobbyistCovered position, as disclosed
JERRY DRISCOLL —
JEFFREY FORBES —
ELIZABETH GREER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual Property and Process Patent Issues - H.R. 1908, Patent Reform Act (all provisions).

LobbyistCovered position, as disclosed
JERRY DRISCOLL —
JEFFREY FORBES —
ELIZABETH GREER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1908 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.